This website uses cookies. By using the site you are agreeing to our Privacy Policy.

Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.

Main menu starts here.
Skip the main menu to current location in your website.

Current location in your website.
Skip to main contents.

What's New


The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.

Announcement of the Acquisition of Marketing Approval for Geninax® Tablet, an Oral New-Type Quinolone Antibiotic agent, in Japan
July 31, 2007

Toyama Chemical Co., Ltd. ("Toyama"; headquarters: Tokyo; President: Masuji Sugata) has received a marketing approval for an oral formulations of its new-type quinolone antibiotic agent, Geninax® (generic name: garenoxacin mesilate hydrate, a development number: T-3811). Toyama has submitted an application for Geninax® on May 30, 2006.

Garenoxacin, a new type of quinolone discovered by Toyama, has strong activity against respiratory tract infection pathogens and otorhinolaryngological infection pathogens including multidrug-resistant S.pneumoniae. It exhibits good oral absorption and tissue distribution, which allows once-daily oral administration, and shows high clinical efficacy.

Development and Sales & Marketing

  • Toyama and Taisho Pharmaceutical Co., Ltd. ("Taisho"; headquarters: Tokyo; President: Akira Uehara) have co-developed Geninax® for the treatment of respiratory infections and otolaryngologic infections in Japan.
  • In March 2006, Toyama and Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) have concluded a basic licensing agreement for the sales & marketing and joint development for Geninax® within Japan. Astellas will distribute the product, which will be co-promoted by Taisho Toyama Pharmaceutical Co., Ltd., ("Taisho Toyama"; headquarters: Tokyo; President: Akira Ohira) and Astellas.

Once Geninax® is launched in Japan, Toyama, Taisho, Taisho Toyama and Astellas will cooperate with each other in order to maximize the product potential in the domestic market.

Taisho Toyama and Astellas will announce the launch timing after it is listed in the NHI drug price list.

Overview of product
Brand name : Geninax® Tablets 200mg
Generic name : garenoxacin mesilate hydrate
Indication : Pharyngo-laryngitis, Tonsillitis, Acute bronchitis, Pneumonia, Secondary infection of chronic respiratory disease, Otitis media, Sinusitis
Dosage and Administration : The usual adult dosage for oral use is 400mg of garenoxacin once daily.
Footer starts here.

Pages ends here.
Move to top of the page.